

No. 23-56

September 12, 2023
Eisai Co., Ltd.

EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.

With the aim of relieving the anxieties of people with dementia and their families and addressing social issues, Eisai is not only creating therapeutic drugs, but also working to build a dementia ecosystem through the development of digital solutions and collaboration with other industries. Theoria technologies will serve as the core of a highly transparent and neutral dementia platform, and the foundation for the development of an ecosystem to empower the people with dementia, regardless of the type or stage of the disease, to "live their fullest lives".

Theoria technologies will accelerate decision-making and strengthen the hiring and training of digital talent under an organizational structure optimized for digital business, and will utilize clinical study data that Eisai has accumulated over many years as well as cohort study data, Personal Health Records (PHR), and other data to develop various prediction algorithms, create digital solutions and provide data. Theoria technologies will commence business activities in April 2024, with the aim of providing services for a risk prediction algorithm for early detection of mild cognitive impairment (MCI) and dementia in FY2024. In addition, together with Eisai, Theoria technologies will develop and provide Sasaeru, an application that helps facilitate communication between people with dementia, doctors, and caregivers by recording Activities of Daily Living (ADL) of the people with dementia. Furthermore, Theoria technologies will promote the development of digital services by strengthening collaboration with other companies.

Eisai is aiming to create social impact by realizing a Dementia Inclusive Society where people with dementia and the people in the daily living domain can live their lives how they would like, through the development of an ecosystem.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to Editors]

1. About Theoria technologies Co., Ltd.

- 1) Company Name: Theoria technologies Co., Ltd.
- 2) Location: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
- 3) Representative: Ryo Jokura
- 4) Scope of Business: Provision of services utilizing medical and health-related data, other healthcare-related services
- 5) Charter Capital: 350 million JPY
- 6) Date of Establishment: September 4, 2023

<Business Model>



2. About algorithms for predicting the risk of developing mild cognitive impairment (MCI) and dementia for early detection

For MCI and dementia, there is a challenge that patients might be unaware of the progression of their symptoms leading to a delay in consultation and diagnosis. By enabling people with dementia to predict their own condition, it is hoped that it will lead to greater implementation of prevention activities and that greater action will be taken toward early diagnosis. The service is aimed for launch in fiscal 2024.

3. About Sasaeru, a communication application for doctors, caregivers and people with mild cognitive impairment (MCI) and dementia

Sasaeru is an application developed by Eisai that records Activities of Daily Living (ADL), which is important information in the treatment of dementia, and allows users to visually capture changes in ADL. Its purpose is to resolve problems with communication in the field of dementia care between doctors, caregivers, and people with dementia. The service launch was announced in May 2023 at the Japan Academy for Alzheimer’s Disease, an academic research society of dementia specialists. From 2024, as a Theoria technologies service and in collaboration with Eisai, proof of concept research will be conducted at even more medical institutions to build evidence and promote nationwide development within Japan.

